ArticleAging2020
PDIA3 correlates with clinical malignant features and immune signature in human gliomas.
Article in Aging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 44 citations in OpenAlex.
- Whole-exome tumor-agnostic ctDNA analysis enhances minimal residual disease detection and reveals relapse mechanisms in localized colon cancer.Nature cancer · 2025Article
- Analysis of Punicalin and Punicalagin Interaction with PDIA3 and PDIA1.International journal of molecular sciences · 2024Article
- A spatiotemporal comparative analysis on tumor immune microenvironment characteristics between neoadjuvant chemotherapy and preoperative immunotherapy for ESCC.Cell death & disease · 2024Article
- Single-cell analysis identified PDIA3 as regulator of malignant characteristics and macrophage function in human cancers.Functional & integrative genomics · 2024Article
- Neuromedin U receptor 1 deletion leads to impaired immunotherapy response and high malignancy in colorectal cancer.iScience · 2024Article
- Comprehensive analysis of CYBB as a prognostic marker and therapeutic target in glioma: A bioinformatics approach.Heliyon · 2024Article
- The role of PDIA3 in oral squamous cell carcinoma and its value as A diagnostic and prognostic biomarker.Heliyon · 2023Article
- The hsa_circ_0000276-ceRNA regulatory network and immune infiltration in cervical cancer.BMC cancer · 2023Article
- Bioinformatics-based identification of lipid- and immune-related biomarkers in abdominal aortic aneurysms.Heliyon · 2023Article
- Protein disulfide isomerase family mediated redox regulation in cancer.Advances in cancer research · 2023Review
- Novel exosome-related risk signature as prognostic biomarkers in glioblastoma.Frontiers in immunology · 2023Article
- CDH6 as a prognostic indicator and marker for chemotherapy in gliomas.Frontiers in genetics · 2022Article
- A Novel Thrombosis-Related Signature for Predicting Survival and Drug Compounds in Glioblastoma.Journal of oncology · 2022Article
- Pan-Cancer Analysis of PDIA3: Identifying It as a Potential Biomarker for Tumor Prognosis and Immunotherapy.Oxidative medicine and cellular longevity · 2022Article
- Application of Proteomics in the Discovery of Radiosensitive Cancer Biomarkers.Frontiers in oncology · 2022Review
- Protein Disulfide-Isomerase A3 Is a Robust Prognostic Biomarker for Cancers and Predicts the Immunotherapy Response Effectively.Frontiers in immunology · 2022Article
- Antigen Presentation Machinery Signature-Derived CALR Mediates Migration, Polarization of Macrophages in Glioma and Predicts Immunotherapy Response.Frontiers in immunology · 2022Article
- Identification of an Inflammatory Response-Related Gene Signature to Predict Survival and Immune Status in Glioma Patients.Journal of immunology research · 2022Article
- Applications of single-cell sequencing in cancer research: progress and perspectives.Journal of hematology & oncology · 2021Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since therapeutic strategies are limited in gliomas, new molecules or biomarkers are essential for diagnosis and therapy. Here, we investigated expression of protein disulfide isomerase family A member 3 (PDIA3) in gliomas to evaluate its potential as a promising immune target or biomarker. Transcriptome level, genomic profiles and its association with clinical practice from TCGA and CGGA databases were analyzed. All statistical analyses were performed using R project. In gliomas with high PDIA3 expression, somatic mutations showed the correlation with loss of PTEN and amplification of EGFR; meanwhile, in PDIA3 low gliomas, mutations in isocitrate dehydrogenase (IDH) took 80%. Moreover, PDIA3 was found to positively correlate with ESTIMATE scores and diverse infiltrating immune and stromal cell types localizing in tumor microenvironment. PDIA3 was found to be highly correlated with macrophage and T cells based on single cell sequencing. Additionally, PDIA3 was also involved in suppression of anti-tumor immunity via multiple immune regulatory processes. Finally, PDIA3 was observed to correlate with other immune checkpoint inhibitors and associated with inflammation. Our findings identified the significance of PDIA3 in the process of gliomas and demonstrated the potential of PDIA3 as a molecular target in prognosis and immune related treatment of gliomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.